Epirubicin hydrochloride combined with capecitabine tablets on serum OPN,VEGF-C and its efficacy in triple-negative breast cancer
10.3969/j.issn.1005-1678.2016.11.035
- VernacularTitle:盐酸表柔比星联合卡培他滨片治疗三阴性乳腺癌患者的临床效果及对血清OPN、VEGF－C的影响
- Author:
Danying XU
;
Yan YUAN
;
Fuming LI
- Keywords:
triple-negative breast cancer;
capecitabine;
epirubicin;
osteopontin
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(11):118-120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore epirubicin hydrochloride combined with capecitabine tablets on serum levels of osteopontin (OPN), vascular endothelial growth factor C ( VEGF-C) and its efficacy in the treatment of patients with triple-negative breast cancer.Methods 80 cases triple-negative breast cancer were selected, randomly divided into two groups, 40 cases in each group.The control group were given epirubicin treatment, joint group on the basis of the control group were combined with capecitabine, 21 days for a course of treatment, four courses of treatment.The serum levels of OPN and VEGF-C pre-and post-treatment were detected, the efficacy and adverse reactions were observed.Results Compared with before treatment, the serum levels of OPN and VEGF-C in two groups were lower post-treatment(P<0.05).Compared with control group, the OPN and VEGF-C levels in joint group were lower (P<0.05), the efficacy was higher and the adverse reaction was lower (P<0.05).Conclusion The epirubicin hydrochloride combined with capecitabine tablets could reduce serum OPN and VEGF-C levels in the treatment of patients with triple-negative breast cancer, with high security.
